55,000 Shares in TG Therapeutics, Inc. $TGTX Bought by Sector Gamma AS

Key Points

• Sector Gamma AS has acquired 55,000 shares of TG Therapeutics, Inc. for approximately $2.17 million, signaling increased institutional interest in the biopharmaceutical company.
• In Q1, several hedge funds boosted their holdings in TG Therapeutics, with Russell Investments Group Ltd. increasing its position by 338.6%, now owning 152,214 shares.
• TG Therapeutics reported $0.17 EPS for the latest quarter, missing expectations, and a revenue of $141.15 million, showing a 92.1% year-over-year increase.

Sector Gamma AS acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 55,000 shares of the biopharmaceutical company's stock, valued at approximately $2,169,000.

A number of other hedge funds also recently made changes to their positions in the company. Fox Run Management L.L.C. purchased a new stake in shares of TG Therapeutics during the first quarter valued at approximately $749,000. Cookson Peirce & Co. Inc. raised its stake in shares of TG Therapeutics by 16.6% during the first quarter. Cookson Peirce & Co. Inc. now owns 32,742 shares of the biopharmaceutical company's stock valued at $1,291,000 after purchasing an additional 4,661 shares during the period. Persistent Asset Partners Ltd grew its stake in TG Therapeutics by 59.2% during the 1st quarter. Persistent Asset Partners Ltd now owns 36,072 shares of the biopharmaceutical company's stock valued at $1,422,000 after purchasing an additional 13,411 shares in the last quarter. Russell Investments Group Ltd. grew its stake in TG Therapeutics by 338.6% during the 1st quarter. Russell Investments Group Ltd. now owns 152,214 shares of the biopharmaceutical company's stock valued at $6,002,000 after purchasing an additional 117,508 shares in the last quarter. Finally, Informed Momentum Co LLC grew its stake in TG Therapeutics by 0.9% during the 1st quarter. Informed Momentum Co LLC now owns 130,070 shares of the biopharmaceutical company's stock valued at $5,129,000 after purchasing an additional 1,147 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research note on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.25.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.64% of the company's stock.

TG Therapeutics Stock Up 1.4%

Shares of TGTX stock traded up $0.39 during trading hours on Wednesday, hitting $28.31. 1,489,737 shares of the company were exchanged, compared to its average volume of 2,896,458. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. TG Therapeutics, Inc. has a one year low of $21.11 and a one year high of $46.48. The business's 50-day simple moving average is $34.40 and its two-hundred day simple moving average is $35.73. The stock has a market capitalization of $4.49 billion, a price-to-earnings ratio of 76.51 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. During the same period in the previous year, the business posted $0.04 EPS. The business's revenue for the quarter was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.